Amgen (1AMGN) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1AMGN Analyst Ratings

Moderate Buy

9 Buy

16 Hold

2 Sell

Based on 27 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1AMGN Stock 12 Month Forecast

Average Price Target

€357.39

▼(-5.59% Downside)

Based on 27 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is €357.39 with a high forecast of €445.18 and a low forecast of €204.79. The average price target represents a -5.59% change from the last price of €378.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"203":"€203","446":"€446","263.75":"€263.8","324.5":"€324.5","385.25":"€385.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":445.184835,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€445.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":357.3866431930435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€357.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":204.7850241,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€204.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[203,263.75,324.5,385.25,446],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,368.15,374.0757565384615,380.00151307692306,385.9272696153846,391.85302615384614,397.7787826923077,403.7045392307692,409.63029576923077,415.5560523076923,421.48180884615385,427.4075653846154,433.33332192307694,439.2590784615385,{"y":445.184835,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,368.15,367.3220494763879,366.4940989527759,365.66614842916385,364.83819790555185,364.0102473819398,363.18229685832773,362.35434633471573,361.52639581110367,360.6984452874916,359.8704947638796,359.04254424026755,358.21459371665554,{"y":357.3866431930435,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,368.15,355.5834633923077,343.01692678461535,330.45039017692307,317.8838535692307,305.31731696153844,292.75078035384615,280.1842437461538,267.6177071384615,255.0511705307692,242.4846339230769,229.9180973153846,217.3515607076923,{"y":204.7850241,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":249.654,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248.632,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.996,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.012,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":286.437,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324.779,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.815,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.957,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.738,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.649,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.745,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373.9,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.15,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€445.18

Average Price Target€357.39

Lowest Price Target€204.79

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

€406.9

Buy

7.49%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mohit Bansal

Wells Fargo

€347.24→€387.31

Hold

2.31%

Upside

Reiterated

10/02/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Arcturus Therapeutics (NASDAQ: ARCT)

Louise Chen

Scotiabank

€400.67→€445.18

Buy

17.60%

Upside

Reiterated

09/29/26

Amgen price target raised to $500 from $450 at ScotiabankAmgen price target raised to $500 from $450 at Scotiabank

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/24/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN) and Imunon (NASDAQ: IMNN)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€326.77→€365.05

Hold

-3.57%

Downside

Reiterated

09/23/26

Jefferies Sticks to Their Hold Rating for Amgen (AMGN)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

―

Hold

―

Reiterated

09/23/26

Leerink Partners Remains a Hold on Amgen (AMGN)

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

09/23/26

Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (NASDAQ: EWTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN)

Geoff Meacham

Citi

€360.6

Hold

-4.74%

Downside

Reiterated

09/23/26

Competitive profile of Amgen's dazodalibep still 'open question,' says CitiCompetitive profile of Amgen's dazodalibep still 'open question,' says Citi

Gary Nachman

Canaccord Genuity

€341.9

Hold

-9.68%

Downside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Adicet Bio (NASDAQ: ACET) and Amgen (NASDAQ: AMGN)

Yaron Werber

TD Cowen

€402.45

Buy

6.31%

Upside

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Terence Flynn

Morgan Stanley

€322.31

Hold

-14.86%

Downside

Reiterated

09/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Ligand Pharma (NASDAQ: LGND) and Compass Therapeutics (NASDAQ: CMPX)

Salveen Richter

Goldman Sachs

€400.67

Buy

5.84%

Upside

Reiterated

09/22/26

Amgen: Strengthening Pipeline and Long-Term Growth Upside Support Buy Rating and Unchanged $450 Price Target

Tazeen Ahmad

Bank of America Securities

€282.25

Sell

-25.44%

Downside

Reiterated

09/22/26

Amgen Underperform Maintained as Dazodalibep Data Uncertainty Limits Upside; $317 Price Target Unchanged

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN), Viking Therapeutics (NASDAQ: VKTX) and Amgen (NASDAQ: AMGN)

Michael Yee

UBS

€391.76→€382.86

Buy

1.14%

Upside

Assigned

09/17/26

Amgen (AMGN) Gets a Buy from UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

€406.9

Buy

7.49%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mohit Bansal

Wells Fargo

€347.24→€387.31

Hold

2.31%

Upside

Reiterated

10/02/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Arcturus Therapeutics (NASDAQ: ARCT)

Louise Chen

Scotiabank

€400.67→€445.18

Buy

17.60%

Upside

Reiterated

09/29/26

Amgen price target raised to $500 from $450 at ScotiabankAmgen price target raised to $500 from $450 at Scotiabank

Christopher Raymond

Raymond James

―

Hold

―

Reiterated

09/24/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN) and Imunon (NASDAQ: IMNN)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€326.77→€365.05

Hold

-3.57%

Downside

Reiterated

09/23/26

Jefferies Sticks to Their Hold Rating for Amgen (AMGN)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

―

Hold

―

Reiterated

09/23/26

Leerink Partners Remains a Hold on Amgen (AMGN)

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

09/23/26

Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (NASDAQ: EWTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Amgen (NASDAQ: AMGN)

Geoff Meacham

Citi

€360.6

Hold

-4.74%

Downside

Reiterated

09/23/26

Competitive profile of Amgen's dazodalibep still 'open question,' says CitiCompetitive profile of Amgen's dazodalibep still 'open question,' says Citi

Gary Nachman

Canaccord Genuity

€341.9

Hold

-9.68%

Downside

Reiterated

09/23/26

Analysts Offer Insights on Healthcare Companies: Celldex (NASDAQ: CLDX), Adicet Bio (NASDAQ: ACET) and Amgen (NASDAQ: AMGN)

Yaron Werber

TD Cowen

€402.45

Buy

6.31%

Upside

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Terence Flynn

Morgan Stanley

€322.31

Hold

-14.86%

Downside

Reiterated

09/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (NASDAQ: AMGN), Ligand Pharma (NASDAQ: LGND) and Compass Therapeutics (NASDAQ: CMPX)

Salveen Richter

Goldman Sachs

€400.67

Buy

5.84%

Upside

Reiterated

09/22/26

Amgen: Strengthening Pipeline and Long-Term Growth Upside Support Buy Rating and Unchanged $450 Price Target

Tazeen Ahmad

Bank of America Securities

€282.25

Sell

-25.44%

Downside

Reiterated

09/22/26

Amgen Underperform Maintained as Dazodalibep Data Uncertainty Limits Upside; $317 Price Target Unchanged

Matt Phipps

William Blair

―

Buy

―

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (NASDAQ: ELDN), Viking Therapeutics (NASDAQ: VKTX) and Amgen (NASDAQ: AMGN)

Michael Yee

UBS

€391.76→€382.86

Buy

1.14%

Upside

Assigned

09/17/26

Amgen (AMGN) Gets a Buy from UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KURAKura Oncology

DNLIDenali Therapeutics

OVIDOvid Therapeutics

HITIHigh Tide

AXGNAxoGen

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

David AmsellemPiper Sandler

Success Rate

14/20 ratings generated profit

Average Return

+5.45%

Copying David Amsellem's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +5.45% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

19/20 ratings generated profit

Average Return

+22.74%

Copying David Amsellem's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +22.74% per trade.

2 Years

Jay OlsonOppenheimer

Success Rate

27/28 ratings generated profit

Average Return

+27.47%

Copying Jay Olson's trades and holding each position for 2 Years would result in 96.43% of your transactions generating a profit, with an average return of +27.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1AMGN Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1AMGN has received 31 Buy Ratings, 33 Hold Ratings, and 4 Sell Ratings. 1AMGN average Analyst price target in the past 3 months is 357.39.

Each month's total comprises the sum of three months' worth of ratings.

1AMGN Financial Forecast

1AMGN Earnings Forecast

Next quarter’s earnings estimate for 1AMGN is €5.16 with a range of €4.89 to €5.49. The previous quarter’s EPS was €5.61. 1AMGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1AMGN has Performed in-line its overall industry.

1AMGN Sales Forecast

Next quarter’s sales forecast for 1AMGN is €8.95B with a range of €8.78B to €9.16B. The previous quarter’s sales results were €8.97B. 1AMGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1AMGN has Performed in-line its overall industry.

1AMGN Stock Forecast FAQ

What is IT:1AMGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 357.39.

What is IT:1AMGN’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IT:1AMGN, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 16 hold ratings and 2 sell ratings.

What is Amgen’s share price target?

The average share price target for Amgen is 357.39. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €445.18 ,and the lowest forecast is €204.79. The average share price target represents -5.59% Decrease from the current price of €378.55.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 27 Wall Streets Analysts.

How can I buy shares of Amgen?

To buy shares of IT:1AMGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Amgen (1AMGN) Stock Forecast & Price Target

1AMGN Analyst Ratings

1AMGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

1AMGN Analyst Recommendation Trends

1AMGN Financial Forecast

1AMGN Earnings Forecast

1AMGN Sales Forecast

1AMGN Stock Forecast FAQ

Detailed List of Analyst Forecasts